China’s Guidebook for Pharmaceutical Patent Protection

Executive Summary
Preface

Chapter 1 Introduction

Chapter 2 Organization Structure of Patent Authorities and Judicial System
2.1. Organization Structure of Patent Authorities
2.2. Organization Structure of Judicial System
2.3. Responsibilities of the State Intellectual Property Office (SIPO)
2.3.1. Responsibilities of the Patent Office
2.3.2. Responsibilities of the Patent Reexamination Board

Chapter 3 The Objects of Patent Right
3.1. The Objects of Patent Right
3.2. The Non-Patentable Subject Matter

Chapter 4 The Patentable Subject Matter Relating to Pharmaceuticals
4.1. The Patentable Subject Matters for Invention
4.2. The Patentable Subject Matters for Utility Model
4.3. The Patentable Subject Matters for Design

Chapter 5 Application for Patent
5.1. The Right of Patent Application
5.2. The Applicant for Patent
5.3. The Date of Filing and the Priority Date
5.3.1. The Date of Filing
5.3.2. The Priority Date
5.4. Application for Patent
5.4.1. Application for a Patent for Invention or Utility Model
5.4.2. Application for a Patent for Design

Chapter 6 Examination and Approval of Application for Patent
6.1. Examination and Approval of Application for Patent for Invention
6.2. Examination and Approval of Application for Patent for Utility Model and Design
6.3. Examination and Approval Procedure of Application for Patent for Invention
6.4. Examination and Approval Procedure of Application for Patent for Utility Model or Design

Chapter 7 Reexamination of Patent Application and Invalidation of Patent Right
7.1. Reexamination of Patent Application
7.2. Reexamination of Invalidation of Patent Right

Chapter 8 Legitimate Rights and Liabilities of Patentee
8.1. Legitimate Rights and Interests of Patentee
8.2. Legitimate Liabilities of Patentee

Chapter 9 Limitation of Patent Right
9.1. Exceptions to Patent Right Conferred
9.2. Compulsory License for Exploitation of Patent

Chapter 10 Protection of Patent Right
10.1. Duration and Scope of Patent Right Protection
10.2. Infringement of Patent Right and Legal Liability of Infringer
10.2.1. Infringement of Patent Right
10.2.2. Legal Liability of Infringer
10.3. Administrative Protection for Patent Right
10.3.1. Administrative Protection of the Patent Authorities
10.3.2. Administrative Protection of the Customs
10.4. Administrative Judicial Procedures for Protection of Patent Right
10.5. Civil Judicial Procedures and Remedies for Patent Right
10.5.1. Scope of Civil Patent Disputes
10.5.2. Jurisdiction
10.5.3. The Time Limit of Litigation
10.5.4. Application for Pre-trial Cessation of Infringement and Property Preservation
10.5.5. Litigation
10.5.6. Remedies and Compensations
10.6. Criminal Punitions for Infringement of Patent Right

Chapter 11 Compositions of Optimized Protection Strategies
11.1. Optimized Patent Protection Strategies based on the Kind of Patent Right
11.1.1. Review of Some Essentials of Knowledge
11.1.2. Compositions of Optimized Patent Protection Strategies based on the Kind of Patent Right
11.1.3. Case Studies
11. 2. Optimized Protection Strategies beyond Patent Right
11.2.1. Case Study: Pfizer’s Viagra Patent and Trademark Dispute in China
11.2.2. Essential Knowledge of Registered Trademark in China
11.2.3. Optimized Protection Strategies beyond Patent Right

Chapter 12 Appendices
12.1. Case 1: A Patent Infringement Dispute of Eli Lilly (Eli Lilly and Company) v. Jiangsu Hansoh Pharmaceutical Corporation & Shanghai Institute of Pharmaceutical Industry in China
12.2. Case 2. A Patent Infringement Dispute of Abbott Laboratories v. Andrx Pharmaceuticals, INC.
12.3. List of the People’s Courts Accepting First Instance Administrative and Civil Litigations for Patent Case
12.4. Patent Registration and Patent Gazette in China
12.4.1. Patent Registration in China
12.4.2. Patent Gazette in China
12.5. References
12.6. Resources
12.7. Author’s Biography
12.8. Company’s Description
12.9. Patent Law of the People’s Republic of China (Revised in 2008)
12.10. Rules for the Implementation of the Patent Law of the People's Republic of China (Revised in 2010)